Insulet的股票在打破了对2025年Q4收入的预期之后上升,其驱动力是对其Omnipod胰岛素系统的强劲需求以及更高的收入。 Insulet's stock rose after beating Q4 2025 earnings expectations, driven by strong demand for its Omnipod insulin systems and higher revenue.

在报告超过预期的2025年第四季度收益后,Insulet (PODD) 股价上,调整后的每股收益为1.55美元,收入为7.838亿美元,同比增长31.2%. Insulet (PODD) shares rose after reporting fourth-quarter 2025 earnings that beat expectations, with adjusted earnings of $1.55 per share and revenue of $783.8 million, a 31.2% year-over-year increase. 该公司将业绩强劲归因于对Omnipod胰岛素运载系统的需求不断增长,包括2型糖尿病患者的扩大使用和国际市场的增长。 The company attributed strong performance to growing demand for its Omnipod insulin delivery systems, including expanded use among Type 2 diabetes patients and international market growth. Insulet提出了其2026年收入指导,指出尽管利息支出增加,比较也更加严格,但势头仍然持续。 Insulet raised its 2026 revenue guidance, citing continued momentum despite higher interest expenses and tougher comparisons. 股票的反应是积极的,反映了投资者对其长期前景的信心。 The stock reacted positively, reflecting investor confidence in its long-term outlook.